Dr Reddy's extends falls; Morgan Stanley, BofA downgrade

Shares in Dr. Reddy's Laboratories Ltd slip 2.3 percent to 2,551 rupees, adding to

RELATED ARTICLES

their 4.1 percent fall on Tuesday as the drugmaker continues to be hit by disappointment over its January-March earnings.

Bank of America-Merrill Lynch downgraded the stock to "underperform" from "buy," and cut its price target to 2,550 rupees from 3,180 rupees, citing a "moderation in core earnings and limited upside."

Morgan Stanley downgraded Dr. Reddy's to "equalweight" from "overweight" and lowered its price target to 2,719 rupees from 3,078 rupees, saying earnings growth could be hit by a "high base in the U.S., limited new launch visibility and rising R&D spending."

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India’s relief-rescue ops in Nepal are part of Modi’s South Asia strategy

    In reacting with alacrity to the earthquake disaster in Nepal, prime minister Narendra Modi has demonstrated two things.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Taslima Nasreen

Will Saudi sex slavery ever end?

An intriguing news item was published in the Arab world ...

Purnendu Ghosh

Err all right, but hiding is wrong

We are human, and therefore, prone to making mistakes. We ...

Shona Adhikari

Art lovers in India are spoilt for choice

Recent art trends point towards the inclusion of a wider ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture